<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5659">
  <stage>Registered</stage>
  <submitdate>19/08/2013</submitdate>
  <approvaldate>19/08/2013</approvaldate>
  <nctid>NCT01926951</nctid>
  <trial_identification>
    <studytitle>Renal Denervation Using Externally Focused Therapeutic Ultrasound</studytitle>
    <scientifictitle>A Feasibility Study: An Evaluation of Renal Denervation Using Externally Focused Therapeutic Ultrasound With External Targeting and Tracking on Patients With Refractory Hypertension</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>KM13-001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hypertension</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Hypertension</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - Surround Sound Externally Focused Therapeutic Ultrasound

Experimental: Renal Denervation - Renal Denervation using the Kona Surround Sound Externally Focused Therapeutic Ultrasound therapy.


Treatment: devices: Surround Sound Externally Focused Therapeutic Ultrasound
Externally Focused Therapeutic Ultrasound using the Kona Surround Sound System

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety - Safety will be assessed by incidence and evaluation of any serious adverse effects associated with the investigational procedure through 52-week evaluation. Included in this assessment will be the proportion of subjects with any of the following outcomes: 1) death, or 2) medical morbidity.</outcome>
      <timepoint>52-week post-treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Clinical Utility - Clinical utility will be evaluated by comparing pre and post therapy systolic and diastolic blood pressure.</outcome>
      <timepoint>52-week post-treatment</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  At least 18 years of age

          -  Average systolic blood pressure at least 160 mmHg

          -  Refractory, stable hypertension despite being treated with at least three hypertensive
             drugs

          -  Two functioning kidneys, defined as eGFR &gt;= 45 ml/min

          -  At least one renal artery on each side which is greater than 4 mm.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  History of nephrectomy or hydronephrosis

          -  Renal stenosis &gt; 50%

          -  Renal stent

          -  Ambulatory blood pressure monitoring 24 hour average systolic blood pressure &lt;= 135
             mmHg

          -  Kidney stones which are symptomatic and/or &gt; 1 cm

          -  History of abdominal surgery within the past 6 months

          -  Heterogeneities in the kidneys (cysts or tumors)

          -  Residual pyelonephritis

          -  History of myocardial infarction, unstable angina pectoris, or cerebrovascular
             accident within the last 6 months

          -  Hemodynamically significant valvular heart disease

          -  Implantable cardioverter defibrillator, pacemaker, neurostimulator or other device
             incompatible with MRI

          -  Body weight &gt; 150 kilograms

          -  Target treatment depth &gt; 14 cm from the skin line

          -  Pregnant, nursing or intends to become pregnant during the trial period</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/09/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>27</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/06/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Brno</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Prague</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Aukland</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Kona Medical Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study will evaluate the effects of renal denervation using externally focused
      therapeutic ultrasound with external targeting and tracking on patients with refractory
      hypertension.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01926951</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>